David Johnson, CEO and co-founder, GigaGen discusses the company’s recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies. David describes how GigaGen’s recombinant IVIG is not tied to plasma supplies and has the potential to provide a high purity, consistent and ultimately safer treatment alternative for patients in need.